Docetaxel Treatment in PTEN- and ERG-aberrant Metastatic Prostate Cancers Pasquale Rescigno, David Lorente, David Dolling, Roberta Ferraldeschi, Daniel.

Slides:

Advertisements

Similar presentations

Volume 68, Issue 6, Pages (December 2015)

Advertisements

European Urology Focus

Volume 155, Issue 3, Pages (March 1996)

Combination chemotherapy with bevacizumab and S-1 for elderly patients with metastatic colorectal cancer (BASIC trial) M. Yoshida, K. Muro, A. Tsuji,

Volume 195, Issue 5, Pages (May 2016)

Oncol Res Treat 2016;39: DOI: /

David Lorente, Karim Fizazi, Christopher Sweeney, Johann S. de Bono

European Urology Focus

Volume 70, Issue 6, Pages (December 2016)

Volume 68, Issue 6, Pages e129-e131 (December 2015)

Volume 53, Issue 4, Pages (April 2008)

Volume 67, Issue 4, Pages (April 2015)

European Urology Oncology

Volume 52, Issue 4, Pages (October 2007)

Volume 71, Issue 2, Pages (February 2017)

Volume 65, Issue 5, Pages (May 2014)

Volume 66, Issue 2, Pages (August 2014)

Consensus Statement on Circulating Biomarkers for Advanced Prostate Cancer Semini Sumanasuriya, Aurelius Omlin, Andrew Armstrong, Gerhardt Attard, Kim.

Intermittent Hormone Therapy: What Is Its Place in Clinical Practice?

Volume 70, Issue 5, Pages (November 2016)

Volume 66, Issue 3, Pages (September 2014)

Volume 70, Issue 5, Pages (November 2016)

Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma Viktor Grünwald, Xun Lin, Daniel Kalanovic,

Volume 70, Issue 4, Pages (October 2016)

Laurent Boccon-Gibod European Urology Supplements

Active Surveillance for Prostate Cancer in a Real-life Cohort: Comparing Outcomes for PRIAS-eligible and PRIAS-ineligible Patients Timo F.W. Soeterik,

Volume 53, Issue 2, Pages (February 2008)

Cytoreductive Radical Prostatectomy in Men with Prostate Cancer and Skeletal Metastases Axel Heidenreich, Nicola Fossati, David Pfister, Nazareno Suardi,

Volume 53, Issue 4, Pages (April 2008)

Volume 66, Issue 2, Pages (August 2014)

Volume 74, Issue 2, Pages (August 2018)

Prostate-Specific Antigen Kinetics and Outcomes in Patients with Bone Metastases from Castration-Resistant Prostate Cancer Treated with or Without Zoledronic.

Lisa M. Brown, MD, MAS, David T. Cooke, MD, Elizabeth A. David, MD

Volume 71, Issue 2, Pages (February 2017)

Selma Masic, Janet E. Cowan, Samuel L. Washington, Hao G

Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Detected via Prostate-specific Membrane Antigen Positron Emission Tomography Andrew.

Volume 73, Issue 5, Pages (May 2018)

Volume 75, Issue 1, Pages (January 2019)

Volume 55, Issue 6, Pages (June 2009)

Treatment Outcomes by Tumor Histology in Eastern Cooperative Group Study E4599 of Bevacizumab with Paclitaxel/Carboplatin for Advanced Non-small Cell.

European Urology Oncology

Heterogeneity in Definitions of High-risk Prostate Cancer and Varying Impact on Mortality Rates after Radical Prostatectomy Matthew Mossanen, Kenneth.

Volume 70, Issue 6, Pages (December 2016)

Intermittent Hormone Therapy: What Is Its Place in Clinical Practice?

Long-Term Hormonal Therapy: Who Would Benefit?

Volume 74, Issue 3, Pages (September 2018)

Kaplan-Meier curves comparing: (A) overall survival for patients treated on trial compared to those outside of a trial; (B) progression-free survival for.

Volume 70, Issue 1, Pages (July 2016)

Volume 71, Issue 4, Pages (April 2017)

Volume 75, Issue 3, Pages (March 2019)

Psychotherapeutic Interventions Targeting Prostate Cancer Patients: A Systematic Review of the Literature Liliana Vartolomei, Shahrokh F. Shariat, Mihai.

Volume 74, Issue 6, Pages (December 2018)

European Urology Oncology

Axel Heidenreich European Urology Supplements

European Urology Oncology

Highlighting Unmet Needs: Real Patients, Difficult Choices

Kaplan-Meier-estimated PFS and OS are presented, with PFS in c-Met high and low patients shown in (A), OS in c-Met high and low patients in (B), PFS in.

European Urology Oncology

Oncoforum Urology: Prostate Cancer 2008 at a Glance

Clinical Utility of Circulating Tumour Cell Androgen Receptor Splice Variant-7 Status in Metastatic Castration-resistant Prostate Cancer Adam Sharp,

Impact of Tumor Size on Local Control and Pneumonitis After Stereotactic Body Radiation Therapy for Lung Tumors Sean M. Parker, BS, R. Alfredo Siochi,

Axel Heidenreich European Urology Supplements

European Urology Oncology

European Urology Oncology

Efficacy of nivolumab in Japanese patients with advanced non-squamous non-small cell lung cancer (A) Kaplan-Meier curve for PFS, (B) Kaplan-Meier curve.

Kaplan-Meier curves for PFS (panel A) and OS (panel B) of patients with mTCC receiving an anti-EGFR based therapy. mTCC, metastatic transverse colon cancer;

Treatment Outcomes by Tumor Histology in Eastern Cooperative Group Study E4599 of Bevacizumab with Paclitaxel/Carboplatin for Advanced Non-small Cell.

Progression-free (a) and overall (b) survival by age subgroup, Kaplan-Meier plots. Progression-free (a) and overall (b) survival by age subgroup, Kaplan-Meier.

Kaplan-Meier (K-M) curves of progression-free survival (PFS) of the entire cohort of patients with metastatic gastric cancer treated with RAD001. Kaplan-Meier.

Kaplan-Meier (K-M) curves of progression-free survival (PFS) in 54 patients with metastatic gastric cancer treated with RAD001. Kaplan-Meier (K-M) curves.

Presentation transcript:

Docetaxel Treatment in PTEN- and ERG-aberrant Metastatic Prostate Cancers Pasquale Rescigno, David Lorente, David Dolling, Roberta Ferraldeschi, Daniel Nava Rodrigues, Ruth Riisnaes, Susana Miranda, Diletta Bianchini, Zafeiris Zafeiriou, Spyridon Sideris, Ana Ferreira, Ines Figueiredo, Semini Sumanasuriya, Joaquin Mateo, Raquel Perez-Lopez, Adam Sharp, Nina Tunariu, Johann S. de Bono European Urology Oncology Volume 1, Issue 1, Pages 71-77 (May 2018) DOI: 10.1016/j.euo.2018.02.006 Copyright © 2018 European Association of Urology Terms and Conditions

Fig. 1 Kaplan-Meier curves for (A) median overall survival (OS) and (B) median progression-free survival (PFS) from the start of docetaxel chemotherapy for patients with PTEN loss and those with PTEN-positive tumors. CI=confidence interval; DTX=docetaxel. European Urology Oncology 2018 1, 71-77DOI: (10.1016/j.euo.2018.02.006) Copyright © 2018 European Association of Urology Terms and Conditions

Fig. 2 Waterfall plot of prostate-specific antigen (PSA) change for patients with PTEN loss and those still PTEN-positive. The bar indicates a 30% decline in PSA from baseline. European Urology Oncology 2018 1, 71-77DOI: (10.1016/j.euo.2018.02.006) Copyright © 2018 European Association of Urology Terms and Conditions